Improved methods for the detection and treatment of endometriosis
A non-invasive diagnostic method for endometriosis using menstrual discharge analysis identifies specific cell types and gene expression patterns, facilitating early and accurate diagnosis and effective treatment.
Patent Information
- Application Number
- JP2024533265
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-02-09
- Filing Date
- 2022-12-05
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-12-05
AI Technical Summary
Endometriosis is a chronic and underdiagnosed disease with vague symptoms, often leading to delayed diagnosis and ineffective treatment, as current diagnostic methods are invasive and not preferred by patients.
A non-invasive method using menstrual discharge samples to analyze stromal cells through qPCR, digital droplet PCR, single-cell RNA sequencing, flow cytometry, or protein analysis to detect endometriosis by identifying specific cell types and gene expression patterns, and treat it with progestins, danazol, or gonadotropin-releasing hormone agonists based on diagnostic results.
Enables accurate and early diagnosis of endometriosis without invasive procedures, allowing targeted treatment to improve patient outcomes and reduce unnecessary interventions.
Smart Images

Figure 2024543228000001 
Figure 2024543228000002 
Figure 2024543228000003
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 286,705, filed December 7, 2021, and U.S. Provisional Patent Application No. 63 / 308,281, filed February 9, 2022, the contents of each of which are incorporated herein by reference. [Background technology]
[0002] The disclosures of all publications, patents, published patent applications and books referenced in this application are hereby incorporated by reference in their entireties into this application in order to more fully describe the state of the art to which this invention pertains.
[0003] Endometriosis is a chronic and underdiagnosed disease affecting 5-10% of women of childbearing age and is characterized by the proliferation of endometrium-like tissue outside the uterus, most commonly in the peritoneal cavity. Delayed diagnosis is a significant problem for the management of this disorder, and treatment is often not initiated until the disease has progressed for many years. Currently, in the United States, it can take 7-10 years per person to diagnose endometriosis. Endometriosis is a very complex disease, with sometimes vague and nonspecific symptoms. For example, many women present with gastrointestinal symptoms and will see a gastroenterologist as part of their diagnostic journey. Therefore, it is crucial to find methods and means for accurate and early diagnosis of endometriosis. Furthermore, adolescent dysmenorrhea can be both endometriosis-related and nonendometriosis-related. To avoid unnecessary or erroneous interventions in this population, it is important to be able to distinguish between patients who would benefit from endometriosis treatment and those who would not benefit from or would be burdened by such treatment.
[0004] Although the exact pathogenesis of endometriosis remains unclear, retrograde menstruation is recognized as a common underlying factor leading to deposition of menstrual discharge (ME) in the peritoneal cavity. Therefore, differences in the cell biology and genetics of cells within ME may explain why endometriosis occurs in only a portion of women. Furthermore, invasive diagnostic techniques are not favored by patients.
[0005] The present invention addresses these needs and provides a method for non-invasively detecting and treating endometriosis. Summary of the Invention
[0006] A method for non-invasively diagnosing endometriosis in a subject includes: passing a sample of menstrual discharge (ME) through (i) a 70 μm pore filter so as to separate ME debris from ME single cells, or (ii) a filter that allows passage of ME single cells but not ME debris (i.e. sloughed endometrial tissue); Collecting the ME tissue pieces; Treating the ME tissue fragments to disaggregate the tissue fragments into cells; subjecting the cells to (i) qPCR and / or digital droplet PCR gene expression analysis, or (ii) single cell RNA sequencing (scRNA-seq) analysis, or (iii) flow cytometry, or (iv) other protein analysis; after that, (1) determining the presence or absence of stromal cells that exhibit a phenotype or gene expression pattern associated with endometriosis based on the results of qPCR gene expression or scRNA-seq analysis or protein expression by flow cytometry; and / or (2) determining the levels of (a) uterine NK cells, (b) B cells, and / or (c) T cells based on the results of the qPCR gene expression or scRNA-seq analysis or flow cytometry or other protein analysis, and determining whether the levels of uterine NK cells, B cells, and T cells are above, below, or within a predetermined control range for the levels of uterine NK cells, B cells, and T cells, respectively; Equipped with the presence of stromal cells exhibiting a phenotype or gene or protein expression pattern associated with endometriosis indicates that the sample is from a subject with endometriosis; and / or A level of B cells and / or T cells above the pre-defined control range and a level of uterine NK cells below the pre-defined control range indicates that the sample is from a subject with endometriosis.
[0007] A method of treating a subject for dysmenorrhea due to endometriosis includes: (A) obtaining an identification of a subject's dysmenorrhea as (a) indicative of endometriosis or (b) not indicative of endometriosis, the identification being determined by a method comprising: passing a sample of menstrual fluid (ME) from the subject through (i) a 70 μm pore filter or (ii) a filter that allows passage of ME single cells but not ME debris, so as to separate ME debris from ME single cells; Collecting the ME tissue pieces; treating the ME tissue fragments with an enzyme to disaggregate the tissue fragments into cells, lyse red blood cells, and deplete neutrophils; subjecting the cells to (i) qPCR or digital droplet PCR for gene expression analysis, (ii) scRNA-seq analysis, (iii) flow cytometry, or (iv) other protein expression analysis; after that, (1) determining the presence or absence of stromal cells that exhibit a phenotype or gene expression pattern associated with endometriosis based on the results of qPCR gene expression or scRNA-seq analysis or protein expression by flow cytometry; and / or (2) determining the levels of (a) uterine NK cells, (b) B cells, and / or (c) T cells based on the results of the qPCR gene expression or scRNA-seq analysis, or flow cytometry or other protein analysis, and determining whether the levels of uterine NK cells, B cells, and T cells are above, below, or within a predetermined control range for the levels of uterine NK cells, B cells, and T cells, respectively; the presence of stromal cells exhibiting a phenotype or protein or gene expression pattern associated with endometriosis indicates that the sample is from a subject with dysmenorrhea indicative of endometriosis; and / or Levels of B cells and / or T cells above the predetermined control range and levels of uterine NK cells below the predetermined control range indicate that the sample is from a subject with dysmenorrhea indicative of endometriosis. The method of treating a subject with dysmenorrhea for endometriosis further comprises: (B) treating a subject identified as having dysmenorrhea indicative of endometriosis with a progestin, a progestin and an estrogen, danazol, a gonadotropin releasing hormone agonist, or a birth control pill to the subject in an amount effective to treat endometriosis.
[0008] The method for determining the efficacy of a treatment for endometriosis includes: assessing the levels of (a) uterine NK cells, (b) B cells, and / or (c) T cells in menstrual fluid of a subject with endometriosis based on baseline levels of stromal cells exhibiting an endometriosis-associated phenotype or gene expression pattern, and / or the results of qPCR gene expression or scRNA-seq analysis or protein expression analysis by any of the methods disclosed herein; treating the subject by performing a laparoscopic surgery or a hysterectomy on the subject, or administering to the subject an amount of a progestin, a progestin and an estrogen, danazol, a gonadotropin releasing hormone agonist, or a birth control pill effective to treat endometriosis; assessing post-treatment levels of stromal cells exhibiting an endometriosis-associated phenotype or gene expression pattern in the subject's menstrual discharge and / or levels of (a) uterine NK cells, (b) B cells, and / or (c) T cells based on the results of qPCR gene expression, scRNA-seq, or protein expression analysis; comparing the post-treatment levels to the subject's baseline levels, where an improvement in the levels of stromal cells exhibiting a phenotype or gene expression pattern associated with endometriosis and / or an improvement in the levels of (a) uterine NK cells, (b) B cells, and / or (c) T cells indicates that the treatment is effective; Equipped with.
[0009] A method for preparing a menstrual flow (ME) sample for analysis to enrich the interstitial cell content of the sample from less than 1% to greater than 10% comprises: passing a sample of menstrual discharge (ME) through (i) a 70 μm pore filter so as to separate ME debris from ME single cells or (ii) a filter that allows passage of ME single cells but not ME debris; collecting ME tissue fragments that did not pass through the filter; enzymatically treating fresh or fixed ME tissue fragments to disaggregate the tissue fragments into cells; freezing the cells in a preservative (e.g., methanol or formaldehyde) before and / or after disaggregating the tissue pieces; and the preparation results in a stromal cell content of greater than 10% in the sample.
[0010] A kit for non-invasively diagnosing endometriosis in a subject comprises a sample of menstrual fluid (ME), (i) a 70 μm pore filter or (ii) a filter that allows the passage of ME single cells but not ME tissue debris, and collagenase, DNase and / or liberase in an amount effective to disaggregate a predetermined amount of ME tissue debris.
[0011] A method of treating endometriosis in a subject comprises obtaining an identification of the subject as in need of treatment for endometriosis, where the subject has been identified as having endometriosis by any of the methods disclosed herein, and treating the subject by performing a laparoscopic or hysterectomy on the subject or administering to the subject an amount of a progestin, a progestin and an estrogen, danazol, a gonadotropin releasing hormone agonist, or a birth control pill effective to treat endometriosis.
[0012] Also provided is a method for identifying a patient at risk for endometriosis by identifying subclinical inflammation of the endometrium (e.g., acute or chronic endometritis), the method comprising: passing a sample of menstrual discharge (ME) through (i) a 70 μm pore filter so as to separate ME debris from ME single cells or (ii) a filter that allows passage of ME single cells but not ME debris; Collecting the ME tissue pieces; using a fresh or fixed piece of tissue; treating the ME tissue fragments to disaggregate the tissue fragments into cells; subjecting the cells to (i) qPCR gene expression analysis, (ii) scRNA-seq analysis, or (iii) protein expression analysis; after that, (1) determining the presence or absence of stromal cells that exhibit a phenotype or gene expression pattern associated with subclinical inflammation of the endometrium based on the results of qPCR gene expression or scRNA-seq analysis or protein expression analysis; and / or (2) determining the levels of (a) uterine NK cells, (b) B cells, and (c) T cells based on the results of the qPCR gene expression or scRNA-seq analysis, and determining whether the levels of uterine NK cells, B cells, and / or T cells are above, below, or within a predetermined control range for the levels of uterine NK cells, B cells, and / or T cells, respectively; Equipped with the presence of stromal cells that exhibit a phenotype or gene expression pattern associated with subclinical inflammation of the endometrium indicates that the sample is from a subject with endometriosis; and / or A level of B cells and / or T cells above the pre-defined control range and a level of uterine NK cells below the pre-defined control range indicates that the sample is from a subject with endometriosis. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] A method for non-invasively diagnosing endometriosis in a subject includes: passing a sample of menstrual discharge (ME) through (i) a 70 μm pore filter so as to separate ME debris from ME single cells or (ii) a filter that allows passage of ME single cells but not ME debris; Collecting the ME tissue pieces; treating the ME tissue fragments to disaggregate the tissue fragments into cells; subjecting the cells to (i) qPCR gene expression analysis, (ii) scRNA-seq analysis, or (iii) protein expression analysis; after that, (1) determining the presence or absence of stromal cells that exhibit a phenotype or gene expression pattern associated with endometriosis based on the results of qPCR gene expression or scRNA-seq analysis or protein expression analysis; and / or (2) determining the levels of (a) uterine NK cells, (b) B cells, and / or (c) T cells based on the results of the qPCR gene expression or scRNA-seq analysis or protein expression analysis, and determining whether the levels of uterine NK cells, B cells, and / or T cells are above, below, or within a predetermined control range for the levels of uterine NK cells, B cells, and / or T cells, respectively; the presence of stromal cells exhibiting a phenotype or gene expression pattern associated with endometriosis indicates that the sample is from a subject with endometriosis; and / or A level of B cells and / or T cells above the pre-defined control range and a level of uterine NK cells below the pre-defined control range indicates that the sample is from a subject with endometriosis.
[0014] In the methods disclosed herein, after the ME tissue pieces are collected, they can be used fresh in subsequent steps or they can be fixed first and then used in subsequent steps.
[0015] A method of treating a subject for dysmenorrhea due to endometriosis includes: (A) obtaining an identification of a subject's dysmenorrhea as (a) indicative of endometriosis or (b) not indicative of endometriosis, the identification being determined by a method comprising: passing a sample of menstrual discharge (ME) through (i) a 70 μm pore filter or (ii) a filter that allows passage of ME single cells but not ME debris, so as to separate ME debris from ME single cells; Collecting the ME tissue pieces; treating the ME tissue fragments to disaggregate the tissue fragments into cells; (i) subjecting the cells to qPCR gene expression analysis, or (ii) scRNA-seq analysis, or subjecting the cells to (iii) flow cytometry, or (iv) other protein expression analysis; after that, (1) determining the presence or absence of stromal cells that exhibit a phenotype or gene expression pattern associated with endometriosis based on the results of qPCR gene expression or scRNA-seq analysis or flow cytometry or other protein expression analysis; and / or (2) determining the levels of (a) uterine NK cells, (b) B cells, and / or (c) T cells based on the results of the qPCR gene expression or scRNA-seq analysis or flow cytometry or other protein expression analysis, and determining whether the levels of uterine NK cells, B cells, and / or T cells are above, below, or within a predetermined control range for the levels of uterine NK cells, B cells, and / or T cells, respectively; the presence of stromal cells exhibiting a phenotype or gene expression pattern associated with endometriosis indicates that the sample is from a subject with dysmenorrhea indicative of endometriosis; and / or Levels of B cells and / or T cells above the predetermined control range and levels of uterine NK cells below the predetermined control range indicate that the sample is from a subject with dysmenorrhea indicative of endometriosis. The method of treating a subject with dysmenorrhea for endometriosis further comprises: (B) treating a subject identified as having dysmenorrhea indicative of endometriosis with a progestin, a progestin and an estrogen, danazol, a gonadotropin releasing hormone agonist, an aromatase inhibitor, or a birth control pill to the subject in an amount effective to treat endometriosis.
[0016] The method for determining the efficacy of a treatment for endometriosis includes: assessing the levels of (a) uterine NK cells, (b) B cells, and / or (c) T cells in menstrual fluid of a subject with endometriosis based on baseline levels of stromal cells exhibiting a phenotype or gene expression pattern associated with endometriosis, and / or the results of qPCR gene expression or scRNA-seq analysis or flow cytometry or other protein expression analysis by the methods described herein; treating the subject by performing a laparoscopic surgery or a hysterectomy on the subject, or administering to the subject an amount of a progestin, a progestin and an estrogen, danazol, a gonadotropin releasing hormone agonist, an aromatase inhibitor, or a birth control pill effective to treat endometriosis; assessing post-treatment levels of stromal cells exhibiting an endometriosis-associated phenotype or gene expression pattern in the subject's menstrual discharge, and / or levels of (a) uterine NK cells, (b) B cells, and / or (c) T cells based on the results of qPCR gene expression or scRNA-seq analysis or flow cytometry or other protein expression analysis; comparing the post-treatment levels to the subject's baseline levels, where an improvement in the levels of stromal cells exhibiting a phenotype or gene expression pattern associated with endometriosis and / or an improvement in the levels of (a) uterine NK cells, (b) B cells, and / or (c) T cells indicates that the treatment is effective; Equipped with. In embodiments, subjects identified as having dysmenorrhea not indicative of endometriosis are treated for dysmenorrhea with a predetermined amount of a nonsteroidal anti-inflammatory drug, in embodiments, the method further comprises one or more additional iterations of the method to determine when treatment can be stopped, where treatment is stopped if no further improvement in post-treatment levels is observed.
[0017] In embodiments, the levels of uterine NK cells, B cells and / or T cells are measured as a fraction or ratio of the relevant cell type as a total cell in the sample. In embodiments, the levels of uterine NK cells, B cells and / or T cells are measured as a fraction or ratio of the relevant cell type as a total cell in the sample and compared to the respective fraction or ratio of the same cell type in a control sample (e.g., from an equivalent but non-endometriotic sample).
[0018] In embodiments, the method further comprises enriching the sample for stromal cells by removing CD45+ cells from the sample prior to performing (i) qPCR gene expression analysis or (ii) scRNA-seq analysis. In embodiments, the method further comprises enriching the sample for stromal cells by removing CD45+ cells from the sample prior to performing flow cytometry or other protein expression analysis.
[0019] In embodiments, a subject identified as having dysmenorrhea not indicative of endometriosis is treated for dysmenorrhea with a predetermined amount of a nonsteroidal anti-inflammatory drug. In embodiments, a subject (a) has or is diagnosed with dysmenorrhea, and (b) is identified as having dysmenorrhea not indicative of endometriosis by (1) not showing the presence of stromal cells that exhibit a phenotype or gene expression pattern associated with endometriosis based on the results of qPCR gene expression or scRNA-seq analysis, or (2) showing levels of uterine NK cells, B cells, and / or T cells within a predetermined control range for the levels of uterine NK cells, B cells, and / or T cells, respectively, which predetermined control range is not associated with the presence of endometriosis.
[0020] In embodiments, the method further comprises enriching the sample for stromal cells by removing CD45+ cells from the sample prior to performing (i) qPCR gene expression analysis, (ii) scRNA-seq analysis or (iii) protein analysis.
[0021] In embodiments, the method further comprises depleting epithelial cells from the sample prior to performing (i) qPCR gene expression analysis or (ii) scRNA-seq analysis. In embodiments, the epithelial cells are removed by a short adhesion step or by using anti-CD325 / EpCAM depletion. In embodiments, the method further comprises isolating epithelial cells from the sample prior to performing (i) qPCR gene expression analysis, (ii) scRNA-seq analysis or (iii) protein analysis. In embodiments, the method further comprises depleting epithelial cells from the sample prior to performing flow cytometry or other protein expression analysis.
[0022] In embodiments, the step of treating the ME tissue fragments is performed with an enzyme to disaggregate the tissue fragments into cells. In embodiments, the step of treating the ME tissue fragments further comprises one or more of lysis of red blood cells and removal of neutrophils. In embodiments, removal of neutrophils is performed by CD66b selection, for example with a CD66b cocktail.
[0023] In embodiments, the method may comprise subjecting the cells to (i) qPCR and / or digital droplet PCR gene expression analysis, (ii) single-cell RNA sequencing (scRNA-seq) analysis, (iii) flow cytometry, or (iv) protein expression analysis.
[0024] In an embodiment, the method is performed on epithelial cells, bone marrow cells, plasma cells, or eosinophils digested from tissue in ME, mutatis mutandis.
[0025] In an embodiment, treating the ME tissue pieces to disaggregate the tissue pieces into cells comprises contacting the ME tissue pieces with collagenase. In an embodiment, the collagenase is collagenase I. In a further embodiment, the tissue pieces are treated with DNase and / or Liberase. In an embodiment, a collagenase I (1 mg / ml) / DNase (0.5 mg / ml) / Liberase mixture is used for 15 minutes / 37° C. on the tissue. In an embodiment, the resulting released cells will undergo RBC lysis, neutrophil depletion and / or Ficoll centrifugation to remove dead cells and / or positive immune selection for specific cell types (stromal cells, T cells, uNK cells, epithelial cells) using antibody-coated magnetic beads before freezing in methanol or other preservatives such as formaldehyde for scRNA-seq analysis, qPCR and / or protein analysis.
[0026] In embodiments, the method further comprises freezing the cells with a preservative after or before disaggregating the tissue pieces. In embodiments, the cryopreservative comprises methanol or formaldehyde. In embodiments, the method further comprises freezing the cells in an RNA stabilizing solution before or after disaggregating the tissue pieces.
[0027] In embodiments, the method includes, prior to performing (i) qPCR gene expression analysis, (ii) scRNA-seq analysis, or (iii) protein expression analysis, lysing red blood cells in the sample; depleting neutrophils from the sample; and Removing dead cells from the sample The signal processing device may further comprise one or more of:
[0028] In an embodiment, the method further comprises passing the ME tissue fragments separated from the ME single cells through a second filter having a pore size of 40 μm, and the step of collecting the ME tissue fragments is performed on the ME tissue fragments that do not pass through the second filter.
[0029] In an embodiment, the sample is collected in a menstrual cup or menstrual sponge.In an embodiment, the ME sample has been previously taken from the subject.
[0030] In embodiments, the method further comprises separating stromal cells, uterine NK cells, B cells and / or T cells, or tissue derived epithelial cells, bone marrow cells, plasma cells, eosinophils or other cell types from each other using surface markers before subjecting the cells to (i) qPCR or digital droplet gene expression analysis, or (ii) scRNA-seq analysis, or (iii) flow cytometry, or (iv) mass spectrometry or other protein expression analysis.
[0031] In embodiments, the separation is performed using fluorescence activated cell sorting or magnetic activated cell sorting.In embodiments, the isolation is performed using fluorescence activated cell sorting or magnetic activated cell sorting.
[0032] In embodiments, the method comprises determining the level of stromal cells based on the results of qPCR gene expression or scRNA-seq analysis. In embodiments, the method comprises determining the level of stromal cells based on the results of digital droplet PCR gene expression or scRNA-seq analysis or protein expression analysis.
[0033] In an embodiment, the method comprises determining the presence or absence of stromal cells exhibiting a phenotype or gene expression pattern associated with endometriosis based on the results of qPCR gene expression or scRNA-seq analysis, but not determining the levels of (a) uterine NK cells, (b) B cells and / or (c) T cells. In an embodiment, the method comprises determining the presence or absence of stromal cells exhibiting a phenotype, gene expression pattern or protein expression pattern associated with endometriosis based on the results of qPCR gene expression or scRNA-seq analysis, but not determining the levels of epithelial cells, myeloid cells, plasma cells or eosinophils digested from tissue in ME. In an embodiment, the method comprises determining the levels of (a) uterine NK cells, (b) B cells and / or (c) T cells based on the results of qPCR gene expression or scRNA-seq analysis, and determining whether the levels of uterine NK cells, B cells and / or T cells (or other tissue derived cell types) are above, below or within a predetermined control range for the levels of uterine NK cells, B cells and / or T cells (or other tissue derived cell types), respectively.
[0034] In embodiments, the subject is a human. In embodiments, the adult subject is premenopausal. In embodiments, the subject is an adolescent. In embodiments, the adolescent is 12 years of age or older but less than 18 years of age.
[0035] In embodiments of the methods, the stromal cells are not cultured or maintained in culture prior to digestion and processing. In embodiments, the cells are not cultured prior to analysis. In embodiments, enzymatic digestion of the tissue sample is not performed until after filtering to remove single cells.
[0036] In embodiments relating to endometriosis, the predetermined control ranges for B cells, T cells, uterine NK cells and / or other tissue derived cell types are determined from one or more ME tissue explants from one or more control subjects without endometriosis. In embodiments relating to acute or chronic endometritis, the predetermined control ranges for B cells, T cells and / or uterine NK cells (or other tissue derived cell types) are determined from one or more ME tissue explants from one or more control subjects without chronic endometritis.
[0037] In embodiments, the genes, proteins and / or nucleic acids referred to herein are from a human.
[0038] A method for preparing a menstrual flow (ME) sample for analysis to enrich the interstitial cell content of the sample from less than 1% to greater than 10% comprises: passing a sample of menstrual discharge (ME) through (i) a 70 μm pore filter so as to separate ME debris from ME single cells or (ii) a filter that allows passage of ME single cells but not ME debris; collecting ME tissue fragments that did not pass through the filter; enzymatically treating fresh or fixed ME tissue fragments to disaggregate the tissue fragments into cells; freezing the cells in a preservative (e.g., methanol or formaldehyde) before or after disaggregating the tissue pieces; Equipped with The preparation results in a stromal cell content of greater than 10% in the sample. In an embodiment, the method further comprises preparing the ME sample for analysis to enrich the stromal cell content in the sample to 20% or more.
[0039] In an embodiment, the method further comprises preparing the ME sample for analysis to enrich the stromal cell content in the sample to 20% or more.
[0040] In an embodiment, the method further comprises obtaining an ME sample from the subject.
[0041] In method embodiments, the stromal cells are stromal fibroblasts (SFCs). In method embodiments, the stromal cells are CD45- / CD326- / CD31- / CD90+ / CD105+ / CD73+. In method embodiments, the stromal cells are CD140b+. In method embodiments, the stromal cells exhibit a phenotype or gene expression pattern associated with endometriosis, the phenotype or gene expression pattern being a pro-inflammatory or senescent phenotype or gene expression pattern.
[0042] In embodiments, the level of uterine NK cells is determined, and the uterine NK cells are proliferative uterine NK cells.
[0043] In embodiments, the proliferative uterine NK cells are positive for the human marker of proliferation Ki-67 protein (encoded by MKI67).
[0044] In embodiments, the level of proliferative uterine NK cells in an endometriotic subject sample is at least 4-fold lower than a control sample from a non-endometriotic subject.
[0045] In embodiments, the level of proliferative uterine NK cells in an endometriotic subject sample is at least 10-fold lower than a control sample from a non-endometriotic subject.
[0046] In embodiments, the method further comprises selecting proliferative uterine NK cells based on expression of a cell proliferation associated marker. In embodiments, the cell proliferation associated marker is a human marker for proliferation Ki-67, CENPF, UBE2C, ASPM, TOP2A, CKS1B, PCLAF or NUSAP1. In embodiments, cells other than proliferative uterine NK cells are depleted from the sample by a method comprising negative antibody selection.
[0047] In embodiments, the step of determining the level of uterine NK cells is based on the results of qPCR gene expression or scRNA-seq analysis, and the method comprises determining whether the expression level of proliferative uterine NK cell human MKI67 or other cell proliferation associated marker is above, below, or within a predetermined control range of proliferative uterine NK cell human MKI67 or other cell proliferation associated marker, respectively.
[0048] In embodiments, the presence or absence of stromal cells exhibiting a phenotype or gene expression pattern associated with endometriosis is determined.
[0049] In embodiments, the presence of stromal cells in a sample that exhibit higher levels of human matrix Gla protein (MGP), interleukin 11 (IL11) or insulin-like growth factor binding protein 1 (IGFBP1) than a control is indicative of a phenotype or gene expression pattern associated with endometriosis.
[0050] A kit for non-invasively diagnosing endometriosis in a subject comprises a sample of menstrual discharge (ME), (i) a 70 μm pore filter or (ii) a filter that allows passage of ME single cells but not ME tissue debris, and collagenase, DNase and / or liberase in an amount effective to disaggregate a predetermined amount of ME tissue debris. In an embodiment, the kit further comprises a predetermined amount of a preservative. In an embodiment, the kit further comprises a predetermined amount of an RNA stabilizing solution. In an embodiment, the preservative comprises methanol or formaldehyde.
[0051] A method of treating endometriosis in a subject comprises obtaining an identification of the subject as in need of treatment for endometriosis, the subject having been identified as having endometriosis by any of the methods disclosed herein, and treating the subject by performing laparoscopic surgery to remove endometriotic lesions or administering to the subject an amount of a progestin, a progestin and an estrogen, danazol, a gonadotropin releasing hormone agonist, an aromatase inhibitor, or a birth control pill in an amount effective to treat endometriosis. In an embodiment, the treatment provides relief from one or more of the following symptoms in the subject: chronic pelvic pain, dysmenorrhea, dyspareunia, difficulty urinating, difficulty with bowel movements, abdominal bloating.
[0052] In an embodiment, laparoscopic surgery is performed to remove the extrauterine lesion.
[0053] Also provided is a method for identifying a patient at risk for endometriosis by identifying subclinical inflammation of the endometrium (e.g., acute or chronic endometritis), the method comprising: passing a sample of menstrual discharge (ME) through (i) a 70 μm pore filter so as to separate ME debris from ME single cells or (ii) a filter that allows passage of ME single cells but not ME debris; Collecting the ME tissue pieces; using a fresh or fixed piece of tissue; treating the ME tissue fragments to disaggregate the tissue fragments into cells; (i) subjecting the cells to qPCR gene expression analysis, or (ii) scRNA-seq analysis, or subjecting the cells to (iii) flow cytometry, or (iv) mass spectrometry or other protein analysis; after that, (1) determining the presence or absence of stromal cells that exhibit a phenotype or gene expression pattern associated with subclinical inflammation of the endometrium based on the results of qPCR gene expression or scRNA-seq analysis or flow cytometry or other protein expression analysis; and / or (2) determining the levels of (a) uterine NK cells, (b) B cells, and (c) T cells based on the results of the qPCR gene expression or scRNA-seq analysis, and determining whether the levels of uterine NK cells, B cells, and / or T cells are above, below, or within a predetermined control range for the levels of uterine NK cells, B cells, and / or T cells, respectively; wherein the presence of stromal cells exhibiting a phenotype or gene expression pattern associated with subclinical inflammation of the endometrium indicates that the sample is from a subject with endometriosis, and / or levels of B cells and / or T cells at or above a predetermined control range and levels of uterine NK cells below a predetermined control range indicate that the sample is from a subject with endometriosis.
[0054] The method can be used here to identify subjects at risk for endometriosis. Also provided is a method of treating subjects at risk for endometriosis by administering to the subject locally or systemically an anti-inflammatory agent that targets a cytokine. In an embodiment, the cytokine is TNF alpha and / or IL1 beta. Anti-inflammatory agents directed against cytokines are well known in the art, such as certain small organic molecules (see, for example, www:ncbi.nlm.nih.gov / pmc / articles / PMC3752337 / , which is incorporated herein by reference), and the anti-cytokine can also be a biologic, such as a monoclonal antibody or a fusion protein directed against a known cytokine, such as TNF alpha or IL-1 beta.
[0055] Menstrual cups described herein include, but are not limited to, those sold by Diva International Inc. of Ontario, Canada. Sponges for collecting ME described herein include, but are not limited to, polyether polyurethane menstrual sponges.
[0056] A method for non-invasively diagnosing endometriosis in a subject includes: passing a sample of menstrual discharge (ME) through (i) a 70 μm pore filter so as to separate ME debris from ME single cells or (ii) a filter that allows passage of ME single cells but not ME debris; Collecting the ME tissue pieces; using a fresh or fixed piece of tissue; treating the ME tissue fragments to disaggregate the tissue fragments into cells; (i) subjecting the cells to qPCR gene expression analysis, or (ii) scRNA-seq analysis, or subjecting the cells to (iii) flow cytometry, or (iv) other protein analysis; after that, determining whether (a) uterine NK cells, (b) B cells, and / or (c) T cells exhibit a gene expression pattern associated with endometriosis based on the results of qPCR gene expression or scRNA-seq analysis or flow cytometry; Equipped with Gene expression patterns in (a) uterine NK cells, (b) B cells and / or (c) T cells associated with endometriosis indicate that the sample is from a subject with endometriosis.
[0057] As used herein, a predetermined control amount is a value that is usually previously determined or obtained as a control. The concept of a control is well established in the art and can be empirically determined, in non-limiting examples, from non-diseased subjects (versus diseased subjects, including diseased subjects with various degrees of associated affliction), and can be normalized as desired (in non-limiting examples, for volume, mass, age, location, sex) to counteract the effects of one or more variables.
[0058] For example, as used herein, "and / or" includes the separate embodiments of (i) Option A, (ii) Option B, and (iii) Option A plus Option B.
[0059] All combinations of the various elements described herein are within the scope of the invention unless otherwise indicated herein or clearly contradicted by context.
[0060] The invention will be better understood from the following Experimental Details, although those skilled in the art will readily appreciate that the specific methods and results described are merely illustrative of the invention that is more fully described in the claims that follow.
[0061] Experimental details The inventors have developed a new method to isolate and study sloughed eutopic endometrial tissue with abundant stromal cells using ME. Also disclosed is a new method of harvesting fresh ME that is practical for both adults and adolescents and can be repeated across menstrual cycles. Importantly, this method can capture the phenotypic state of eutopic endometrium at the time ME tissue is delivered into the peritoneal cavity. Furthermore, innovations are disclosed to allow scRNA-Seq, qPCR or protein analysis (or other sequencing methods) to be conveniently and cost-effectively "batched" and performed on multiple samples and analyzed simultaneously, e.g., using Demuxlet, by rapid digestion of endometrial tissue fragments in ME, followed or preceded by fixation in preservatives, e.g., methanol or formaldehyde, permeabilization and / or freezing. This innovation also allows these analyses to be applied to multiple patient ME samples compared to control ME samples, in addition to repeated ME sampling over time to ensure reproducibility. The results provide a complete analysis of multiple ME cell types and individual cell subsets, including fresh stromal cells, epithelial cells, uterine NK cells, T cells, B cells and other immune system cells. Interestingly, the differences from the cultured samples are quite striking, as described below.
[0062] Study population: Subject recruitment / enrollment was via the ROSE study with over 1500 participants.
[0063] Decidualization failure in ME-eSC: It has been previously shown that decidualization failure associated with endometriosis is readily observable in cultured endometrial stromal cells (ME-eSC) derived from menstrual discharge (14, 16, 17). Moreover, subjects with symptoms of endometriosis without a confirmed diagnosis have a similar failure. ME-eSC (p1) from endometriotic subjects show a marked decidualization failure, reflected in the production of IGFBP1 by ELISA comparing cAMP to vehicle after 24 hours (IGFBP1 ratio). Up to 10% of control subjects have a relatively low decidualization capacity. Despite the high accuracy of this observed correlation, this approach presents many challenges in the development of a diagnostic. Because ME-eSC represent only 1–3% of the isolated free mononuclear cells of fresh ME, these assays require the culture of these cells. Although this is not difficult, it is very time-consuming and expensive, thus limiting its use as a diagnostic test.
[0064] Endometrial tissue is abundant in ME: In the course of processing many samples of ME collected using menstrual cups, it was observed that there were chunks of endometrial tissue present that were not captured by the initial approach. These could be demonstrated by filtering the ME, for example through a 70 μm filter, to enrich for such fragments. Doing this with multiple samples, it was discovered that intact endometrial tissue was readily demonstrable by histological analysis of the ME. Photomicrographs of samples showed the presence of fragments of endometrial tissue containing both epithelial and stromal cells, as well as uNK cells. Immunostaining confirmed the presence of endometrial stromal cells (CD10) and uNK cells (CD56) in five individuals.
[0065] Several approaches were explored for processing the “whole ME” containing these tissue fragments for scRNA-Seq analysis. First, whole ME samples were digested with collagenase and DNase to release cells from the tissue fragments, then filtered to capture cells released by digestion as well as free single cells in the ME. Magnetic beads were used to deplete neutrophils, which served as a source of genomic DNA for DEMUXLET analysis (neutrophils dominate the single cell content in ME). This was followed by density gradient separation using Ficoll to remove dead cells. The resulting single cell preparations were frozen in methanol for subsequent single cell processing, library construction, and scRNA-Seq analysis on the 10X Genomics platform (18). Some samples were processed fresh to compare with methanol freezing.
[0066] Before proceeding with detailed analysis of many samples, we sought to assess the bias that may be induced by methanol freezing of samples by the method of Chen (18). To do so, we compared results from single-cell processed samples of fresh cells with results from samples processed after freezing in methanol. When comparing 10X Genomics processing for scRNA-Seq with methanol fixation to ME cells freshly processed for scRNA-Seq analysis, the results were nearly indistinguishable.
[0067] With the feasibility of this approach established, we performed scRNA-Seq analysis of ME samples from 11 subjects, including samples from 3 controls, 4 patients with confirmed endometriosis, and 4 patients with symptoms (and impaired decidualization) strongly suggestive of endometriosis. UMAP plots revealed that several distinct cell clusters were visible in these ME samples. This included stromal cells, NK cells, B cells, and several subsets of T cells and myeloid cells that clustered towards the center of the plot. Small numbers of epithelial cells (less than 2-3% of the total) were also seen. To understand the distribution of these various clusters, comparing control, endometriosis, and symptomatic groups, the results were plotted separately for each group. Simple inspection revealed that the cell counts of some clusters were quite different between clinical groups, especially between uNK cells, B cells, and some T cell subsets. An analysis of odds ratios (ORs) for enrichment of these three clusters was performed comparing endometriosis (endo) cases with controls. Both B cells and some T cell subsets were nearly four-fold enriched in ME enriched in enzyme-digested tissue from endometriosis cases, with uterine NK (uNK) cells being highly enriched in ME from controls compared to endometriosis cases. Importantly, in previous studies, B cells and T cells were unchanged in endometriosis subjects versus controls (see, e.g., U.S. Patent Application Publication No. 2021-0096137), whereas the present method showed a clear difference in that B cells and T cells were unchanged in endometriosis subjects versus controls.
[0068] We also investigated the pattern of gene expression in endometrial stromal cells between endometriosis cases and controls. Surprisingly, IGFBP1 mRNA expression is markedly decreased in endometriosis patients compared to controls in fresh cells. Thus, the data suggest that analysis of IGFBP1 expression in fresh stromal cells during ME (Table 1) may indeed provide a similar diagnostic capacity as decidualization-induced IGFBP1 protein expression observed in cultured stromal cells after decidualization.
[0069] Table 1. Expression of IGFBP1 in fresh ME-derived stromal cells from endometriosis (ENDO) and control (Ctrl) subjects by scRNA-Seq.
[0070] [Table 1]
[0071] Furthermore, scRNA-Seq enabled the study of subsets of stromal cells, revealing further gene expression differences between endometriosis patients (cases) and controls. scRNA-Seq showed that stromal cell subclusters presented distinct gene expression patterns in controls compared to endometriosis cases. High expression of both IGFBP1 and LEFTY2 was found in controls compared to endometriosis in cluster 2, with fold changes ranging from 7 to 8 (log2 approx. 2.6 to 2.8). These transcripts are strongly associated with decidualization. In contrast, cluster 1 was enriched in IL-11 and matrix metalloproteinases in endometriosis cases.
[0072] Alternatively, qPCR can be performed as a transcriptional gene expression analysis. The scRNA-Seq results show that both IGFBP1 and the late decidualization marker LEFTY2 are significantly increased in cluster 2 of ME stromal cells from controls compared to ME stromal cells from endometriosis cases. Again, this strongly suggests that the hypodecidualization phenotype seen in cultured stromal cells can indeed be captured in freshly isolated ME-derived endometrial stromal cells from endometriosis cases, which is surprising.
[0073] Given these results, we continued our experiments to find an improved method to enrich for ME endometrial tissue. We compared the results of this scRNA-seq analysis with a previous report in which free single cells in ME were harvested and FACS analysis was performed on them (14). In this recent approach, all other free ME cells were filtered out prior to tissue digestion and analysis to specifically enrich and select for only tissue fragments. This differs from the process outlined above, in which tissue digestion of the entire ME content was performed, resulting in all free cells in the ME (neutrophil and erythrocyte depleted) and cells released from the digested tissue. A comparison was made between scRNA-Seq of free cells in the entire ME and results after enrichment of specific tissue fragments and recovery on a 70 μm filter prior to digestion and scRNA-Seq. Analysis of scRNA-Seq results for undigested fresh ME (free single cells) was performed compared to enriched / digested ME endometrial tissue (right panel). One subject provided ME using a Diva Cup (Diva International, Inc., Kitchener, Ontario, Canada) (upper panel), and the other utilized external pad collection (lower panel). ME-derived samples enriched for enzymatically digested endometrial tissue showed dramatic enrichment of both stromal and epithelial cells.
[0074] A dramatic enrichment of both CD45neg stromal and epithelial cells was seen in the processed ME endometrial tissue samples compared to fresh single cell suspensions in ME (no tissue). Interestingly, T cell, B cell and NK cell fractions were also present in both types of samples. Naturally, subsets and gene expression patterns in these groups may differ between tissue and ME single cells, but in our view, the most interesting results will be seen in the tissue-derived cells.
[0075] Publications in the Field 1. Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN and Vigano P. Endometriosis. Nat Rev Dis Primers. 2018;4:9.30026507 2. Zondervan KT, Becker CM and Missmer SA. Endometriosis. N Engl J Med. 2020;382:1244-1256.32212520 3. Simoens S, Hummelshoj L and D'Hooghe T. Endometriosis: cost estimates and methodological perspective. HumReprodUpdate. 2007;13:395-404 4. Marquardt RM, Kim TH, Shin JH and Jeong JW. Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis? Int J Mol Sci. 2019;20.31387263 PMC6695957 5. Brosens I, Brosens JJ and Benagiano G. The eutopic endometrium in endometriosis: are the changes of clinical significance? Reprod Biomed Online. 2012;24:496-502.22417665 6. Liu H and Lang JH. Is abnormal eutopic endometrium the cause of endometriosis? The role of eutopic endometrium in pathogenesis of endometriosis. Med Sci Monit. 2011;17:RA92-9.21455119 PMC3539524 7. Drury JA, Parkin KL, Coyne L, Giuliani E, Fazleabas AT and Hapangama DK. The dynamic changes in the number of uterine natural killer cells are specific to the eutopic but not to the ectopic endometrium in women and in a baboon model of endometriosis. Reprod Biol Endocrinol. 2018;16:67.30021652 PMC6052567 8. Chehna-Patel N, Sachdeva G, Gajbhiye R, Warty N and Khole V. "Spot"-ting differences between the ectopic and eutopic endometrium of endometriosis patients. Fertil Steril. 2010;94:1964-71, 1971 e1.20236630 9. Bulun SE, Cheng YH, Yin P, Imir G, Utsunomiya H, Attar E, Innes J and Julie Kim J. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol. 2006;248:94-103.16406281 10. Aghajanova L and Giudice LC. Molecular evidence for differences in endometrium in severe versus mild endometriosis. ReprodSci. 2011;18:229-251 11. Klemmt PA, Carver JG, Kennedy SH, Koninckx PR and Mardon HJ. Stromal cells from endometriotic lesions and endometrium from women with endometriosis have reduced decidualization capacity. FertilSteril. 2006;85:564-572 12. Sumathi VP and McCluggage WG. CD10 is useful in demonstrating endometrial stroma at ectopic sites and in confirming a diagnosis of endometriosis. J Clin Pathol. 2002;55:391-2.11986349 PMC1769659 13. McKinnon B, Mueller M and Montgomery G. Progesterone Resistance in Endometriosis: an Acquired Property? Trends Endocrinol Metab. 2018;29:535-548.29934050 14. Nayyar A, Saleem MI, Yilmaz M, DeFranco M, Klein G, Elmaliki KM, Kowalsky E, Chatterjee PK, Xue X, Viswanathan R, Shih AJ, Gregersen PK and Metz CN. Menstrual Effluent Provides a Novel Diagnostic Window on the Pathogenesis of Endometriosis. Frontiers in Reproductive Health. 2020;2:1-13 15. Warren LA, Shih A, Renteira SM, Seckin T, Blau B, Simpfendorfer K, Lee A, Metz CN and Gregersen PK. Analysis of menstrual effluent: diagnostic potential for endometriosis. Mol Med. 2018;24:1.30134794 PMC6016873 16. Szwarc MM, Hai L, Gibbons WE, Peavey MC, White LD, Mo Q, Lonard DM, Kommagani R, Lanz RB, DeMayo FJ and Lydon JP. Human endometrial stromal cell decidualization requires transcriptional reprogramming by PLZF. Biol Reprod. 2018;98:15-27.29186366 PMC5819842 17. Takamoto N, Zhao B, Tsai SY and DeMayo FJ. Identification of Indian hedgehog as a progesterone-responsive gene in the murine uterus. Mol Endocrinol. 2002;16:2338-48.12351698 18. Gellersen B and Brosens JJ. Cyclic decidualization of the human endometrium in reproductive health and failure. EndocrRev. 2014;35:851-905 19. Shoupe D. The Progestin Revolution: progestins are arising as the dominant players in the tight interlink between contraceptives and bleeding control. Contracept Reprod Med. 2021;6:3.33517911 PMC7849131 20. Gynecologists TACoOa. Age Related Fertility Decline. Committee Opinion. 2014, reaffirmed 2018;589:1-3 21. Vitonis AF, Vincent K, Rahmioglu N, Fassbender A, Buck Louis GM, Hummelshoj L, Giudice LC, Stratton P, Adamson GD, Becker CM, Zondervan KT and Missmer SA. World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: II. Clinical and covariate phenotype data collection in endometriosis research. FertilSteril. 2014;102:1223-1232 22. van Eijk AM, Zulaika G, Lenchner M, Mason L, Sivakami M, Nyothach E, Unger H, Laserson K and Phillips-Howard PA. Menstrual cup use, leakage, acceptability, safety, and availability: a systematic review and meta-analysis. Lancet Public Health. 2019;4:e376-e393.31324419 PMC6669309 23. Michalski SA, Chadchan SB, Jungheim ES and Kommagani R. Isolation of Human Endometrial Stromal Cells for In Vitro Decidualization. J Vis Exp. 2018.30222162 PMC6235076 24. Chen J, Cheung F, Shi R, Zhou H, Lu W and Consortium CHI. PBMC fixation and processing for Chromium single-cell RNA sequencing. J Transl Med. 2018;16:198.30016977 PMC6050658 25. Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S, Goodman SM, Tabechian D, Hughes LB, Salomon-Escoto K, Watts GFM, Jonsson AH, Rangel-Moreno J, Meednu N, Rozo C, Apruzzese W, Eisenhaure TM, Lieb DJ, Boyle DL, Mandelin AM, 2nd, Accelerating Medicines Partnership Rheumatoid A, Systemic Lupus Erythematosus C, Boyce BF, DiCarlo E, Gravallese EM, Gregersen PK, Moreland L, Firestein GS, Hacohen N, Nusbaum C, Lederer JA, Perlman H, Pitzalis C, Filer A, Holers VM, Bykerk VP, Donlin LT, Anolik JH, Brenner MB and Raychaudhuri S. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol. 2019;20:928-942.31061532 PMC6602051 26. Yu J, Berga SL, Zou W and Taylor RN. Interleukin-1beta inhibits estrogen receptor-alpha, progesterone receptors A and B and biomarkers of human endometrial stromal cell differentiation: implications for endometriosis. Mol Hum Reprod. 2019;25:625-637.31408162 PMC6821275 27. Hall OJ and Klein SL. Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sites. Mucosal Immunol. 2017;10:1097-1107.28401937 28. Scarpin KM, Graham JD, Mote PA and Clarke CL. Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl Recept Signal. 2009;7:e009.20087430 PMC2807635 29. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update. 2006;12:169-78.16291771 30. Reis FM, Coutinho LM, Vannuccini S, Batteux F, Chapron C and Petraglia F. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020;26:565-585.32412587 PMC7317284 31. Bedaiwy MA, Dahoud W, Skomorovska-Prokvolit Y, Yi L, Liu JH, Falcone T, Hurd WW and Mesiano S. Abundance and Localization of Progesterone Receptor Isoforms in Endometrium in Women With and Without Endometriosis and in Peritoneal and Ovarian Endometriotic Implants. Reprod Sci. 2015;22:1153-61.26037298 PMC5933169 32. Gronemeyer H, Meyer ME, Bocquel MT, Kastner P, Turcotte B and Chambon P. Progestin receptors: isoforms and antihormone action. J Steroid Biochem Mol Biol. 1991;40:271-8.1958531 33. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H and Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990;9:1603-14.2328727 PMC551856 34. Giangrande PH, Kimbrel EA, Edwards DP and McDonnell DP. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol. 2000;20:3102-15.10757795 PMC85605 35. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA, Jr., Shyamala G, Conneely OM and O'Malley BW. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 1995;9:2266-78.7557380 36. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP and Conneely OM. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science. 2000;289:1751-4.10976068 37. Patel BG, Rudnicki M, Yu J, Shu Y and Taylor RN. Progesterone resistance in endometriosis: origins, consequences and interventions. Acta Obstet Gynecol Scand. 2017;96:623-632.28423456 38. Bergqvist A, Ljungberg O and Skoog L. Immunohistochemical analysis of oestrogen and progesterone receptors in endometriotic tissue and endometrium. Hum Reprod. 1993;8:1915-22.8288760 39. Igarashi TM, Bruner-Tran KL, Yeaman GR, Lessey BA, Edwards DP, Eisenberg E and Osteen KG. Reduced expression of progesterone receptor-B in the endometrium of women with endometriosis and incocultures of endometrial cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Fertil Steril. 2005;84:67-74.16009159 40. Gentilini D, Vigano P, Vignali M, Busacca M, Panina-Bordignon P, Caporizzo E and Di Blasio AM. Endometrial stromal progesterone receptor-A / progesterone receptor-B ratio: no difference between women with and without endometriosis. Fertil Steril. 2010;94:1538-1540.20097334 41. Nisolle M, Casanas-Roux F, Wyns C, de Menten Y, Mathieu PE and Donnez J. Immunohistochemical analysis of estrogen and progesterone receptors in endometrium and peritoneal endometriosis: a new quantitative method. Fertil Steril. 1994;62:751-9.7523199 42. Storer CL, Dickey CA, Galigniana MD, Rein T and Cox MB. FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol Metab. 2011;22:481-90.21889356 PMC3229651 43. Tranguch S, Cheung-Flynn J, Daikoku T, Prapapanich V, Cox MB, Xie H, Wang H, Das SK, Smith DF and Dey SK. Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. Proc Natl Acad Sci U S A. 2005;102:14326-31.16176985 PMC1242310 44. Tranguch S, Wang H, Daikoku T, Xie H, Smith DF and Dey SK. FKBP52 deficiency-conferred uterine progesterone resistance is genetic background and pregnancy stage specific. J Clin Invest. 2007;117:1824-34.17571166 PMC1888571 45. Hirota Y, Tranguch S, Daikoku T, Hasegawa A, Osuga Y, Taketani Y and Dey SK. Deficiency of immunophilin FKBP52 promotes endometriosis. Am J Pathol. 2008;173:1747-57.18988805 PMC2626386 46. Maguire O, Collins C, O'Loughlin K, Miecznikowski J and Minderman H. Quantifying nuclear p65 as a parameter for NF-kappaB activation: Correlation between ImageStream cytometry, microscopy, and Western blot. Cytometry A. 2011;79:461-9.21520400 PMC3140714 47. Stone RC, Feng D, Deng J, Singh S, Yang L, Fitzgerald-Bocarsly P, Eloranta ML, Ronnblom L and Barnes BJ. Interferon regulatory factor 5 activation in monocytes of systemic lupus erythematosus patients is triggered by circulating autoantigens independent of type I interferons. Arthritis Rheum. 2012;64:788-98.21968701 PMC3288585 48. Reyes M, Billman K, Hacohen N and Blainey PC. Simultaneous profiling of gene expression and chromatin accessibility in single cells. Adv Biosyst. 2019;3.31853478 PMC6919553 49. Skene PJ and Henikoff S. An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. Elife. 2017;6.28079019 PMC5310842 50. Meers MP, Bryson TD, Henikoff JG and Henikoff S. Improved CUT&RUN chromatin profiling tools. Elife. 2019;8.31232687 PMC6598765 51. Zuba-Surma EK, Kucia M, Abdel-Latif A, Lillard JW, Jr. and Ratajczak MZ. The ImageStream System: a key step to a new era in imaging. Folia Histochem Cytobiol. 2007;45:279-90.18165167 52. Banga J, Srinivasan D, Sun CC, Thompson CD, Milletti F, Huang KS, Hamilton S, Song S, Hoffman AF, Qin YG, Matta B, LaPan M, Guo Q, Lu G, Li D, Qian H, Bolin DR, Liang L, Wartchow C, Qiu J, Downing M, Narula S, Fotouhi N, DeMartino JA, Tan SL, Chen G and Barnes BJ. Inhibition of IRF5 cellular activity with cell-penetrating peptides that target homodimerization. Sci Adv. 2020;6:eaay1057.32440537 PMC7228753 53. De S, Zhang B, Shih T, Singh S, Winkler A, Donnelly R and Barnes BJ. B Cell-Intrinsic Role for IRF5 in TLR9 / BCR-Induced Human B Cell Activation, Proliferation, and Plasmablast Differentiation. Front Immunol. 2017;8:1938.29367853 PMC5768180 54. Li D, Matta B, Song S, Nelson V, Diggins K, Simpfendorfer KR, Gregersen PK, Linsley P and Barnes BJ. IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE. JCI Insight. 2020;5.31877114 PMC7098722 55. Song S, De S, Nelson V, Chopra S, LaPan M, Kampta K, Sun S, He M, Thompson CD, Li D, Shih T, Tan N, Al-Abed Y, Capitle E, Aranow C, Mackay M, Clapp WL and Barnes BJ. Inhibition of IRF5 hyperactivation protects from lupus onset and severity. J Clin Invest. 2020;130:6700-6717.32897883 PMC7685739 56. Winkler A, Sun W, De S, Jiao A, Nusrat Sharif M, Symanowicz PT, Athale S, Shin JH, Wang J, Jacobson BA, Ramsey SJ, Dower K, Andreyeva T, Liu H, Hegen M, Homer BL, Brodfuehrer J, Tilley M, Gilbert SA, Danto SI, Beebe JJ, Barnes BJ, Pascual V, Lin LL, Kilty I, Fleming M and Rao VR. The IRAK4 kinase inhibitor PF-06650833 blocks inflammation in preclinical models of rheumatologic disease and in humans enrolled in a randomized clinical trial. Arthritis Rheumatol. 2021.34423919 57. Buenrostro JD, Wu B, Chang HY and Greenleaf WJ. ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. Curr Protoc Mol Biol. 2015;109:21 29 1-9.25559105 PMC4374986 58. Buenrostro JD, Giresi PG, Zaba LC, Chang HY and Greenleaf WJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods. 2013;10:1213-8.24097267 PMC3959825 59. Taylor RN, Kane MA and Sidell N. Pathogenesis of Endometriosis: Roles of Retinoids and Inflammatory Pathways. Semin Reprod Med. 2015;33:246-56.26132929 PMC4745121 60. Chantalat E, Valera MC, Vaysse C, Noirrit E, Rusidze M, Weyl A, Vergriete K, Buscail E, Lluel P, Fontaine C, Arnal JF and Lenfant F. Estrogen Receptors and Endometriosis. Int J Mol Sci. 2020;21.32316608 PMC7215544 61. Park S, Lim W, Bazer FW, Whang KY and Song G. Quercetin inhibits proliferation of endometriosis regulating cyclin D1 and its target microRNAs in vitro and in vivo. J Nutr Biochem. 2019;63:87-100.30359864 62. Jamali N, Zal F, Mostafavi-Pour Z, Samare-Najaf M, Poordast T and Dehghanian A. Ameliorative Effects of Quercetin and Metformin and Their Combination Against Experimental Endometriosis in Rats. Reprod Sci. 2021;28:683-692.33141412 63. Patel B, Elguero S, Thakore S, Dahoud W, Bedaiwy M and Mesiano S. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum Reprod Update. 2015;21:155-73.25406186 PMC4366574 64. Ahn SH, Edwards AK, Singh SS, Young SL, Lessey BA and Tayade C. IL-17A Contributes to the Pathogenesis of Endometriosis by Triggering Proinflammatory Cytokines and Angiogenic Growth Factors. J Immunol. 2015;195:2591-600.26259585 PMC4561197 65. Maia H, Jr., Haddad C, Coelho G and Casoy J. Role of inflammation and aromatase expression in the eutopic endometrium and its relationship with the development of endometriosis. Womens Health (Lond). 2012;8:647-58.23181530 66. Matteo M, Cicinelli E, Neri M, Carrubba R, Carpagnano FA, Romeo F, Scutiero G, Greco P, Garlanda C, Vendemiale G, Levi Setti PE and Serviddio G. Pro-inflammatory M1 / Th1 type immune network and increased expression of TSG-6 in the eutopic endometrium from women with endometriosis. Eur J Obstet Gynecol Reprod Biol. 2017;218:99-105.28963923 67. Vallve-Juanico J, Houshdaran S and Giudice LC. The endometrial immune environment of women with endometriosis. Hum Reprod Update. 2019;25:564-591.31424502 PMC6737540 68. Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A and McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm Res. 2016;65:183-92.26650031 69. Cakmak H, Seval-Celik Y, Arlier S, Guzeloglu-Kayisli O, Schatz F, Arici A and Kayisli UA. p38 Mitogen-Activated Protein Kinase is Involved in the Pathogenesis of Endometriosis by Modulating Inflammation, but not Cell Survival. Reprod Sci. 2018;25:587-597.28845752 70. Payan-Carreira R, Pires MA, Strom Holst B and Rodriguez-Martinez H. Tumour necrosis factor in the canine endometrium: an immunohistochemical study. Reprod Domest Anim. 2011;46:410-8.20880318 71. Tabibzadeh S. Ubiquitous expression of TNF-alpha / cachectin immunoreactivity in human endometrium. Am J Reprod Immunol. 1991;26:1-4.1741931 72. Hunt JS, Chen HL, Hu XL and Tabibzadeh S. Tumor necrosis factor-alpha messenger ribonucleic acid and protein in human endometrium. Biol Reprod. 1992;47:141-7.1637942 [ PMC free article ] [ PubMed ] 73. Okuda K, Sakumoto R, Okamoto N, Acosta TJ, Abe H, Okada H, Sinowatz F and Skarzynski DJ. Cellular localization of genes and proteins for tumor necrosis factor-alpha (TNF), TNF receptor types I and II in bovine endometrium. Mol Cell Endocrinol. 2010;330:41–8.20705117 [ PMC free article ] [ PubMed ] 74. Cicinelli E, Trojano G, Mastromauro M, Vimercati A, Marinaccio M, Mitola PC, Resta L and de Ziegler D. Higher prevalence of chronic endometritis in women with endometriosis: a possible etiopathogenetic link. Fertile Sterile. 2017;108:289–295e1.28624114 [ PMC free article ] [ PubMed ] 75. Takebayashi A, Kimura F, Kishi Y, Ishida M, Takahashi A, Yamanaka A, Takahashi K, Suginami H and Murakami T. The association between endometriosis and chronic endometritis. PLoS One. 2014;9:e88354.24558386 PMC3928198 76. Tortorella C, Piazzolla G, Matteo M, Pinto V, Tinelli R, Sabba C, Fanelli M and Cicinelli E. Interleukin-6, interleukin-1beta, and tumor necrosis factor alpha in menstrual effluents as biomarkers of chronic endometritis. Fertil Steril. 2014;101:242-7.24314919 77. Wu D, Kimura F, Zheng L, Ishida M, Niwa Y, Hirata K, Takebayashi A, Takashima A, Takahashi K, Kushima R, Zhang G and Murakami T. Chronic endometritis modifies decidualization in human endometrial stromal cells. Reprod Biol Endocrinol. 2017;15:16.28259137 PMC5336610 78. Barragan F, Irwin JC, Balayan S, Erikson DW, Chen JC, Houshdaran S, Piltonen TT, Spitzer TL, George A, Rabban JT, Nezhat C and Giudice LC. Human Endometrial Fibroblasts Derived from Mesenchymal Progenitors Inherit Progesterone Resistance and Acquire an Inflammatory Phenotype in the Endometrial Niche in Endometriosis. Biol Reprod. 2016;94:118.27075616 PMC4939744 79. Malvezzi H, Hernandes C, Piccinato C and Podgaec S. Interleukin in endometriosis-associated infertility-pelvic pain: systematic review and meta-analysis. Reproduction. 2019.30933927 80. Machairiotis N, Vasilakaki S and Thomakos N. Inflammatory Mediators and Pain in Endometriosis: A Systematic Review. Biomedicines. 2021;9.33435569 PMC7826862 81. D'Hooghe TM, Nugent NP, Cuneo S, Chai DC, Deer F, Debrock S, Kyama CM, Mihalyi A and Mwenda JM. Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Biol Reprod. 2006;74:131-6.16177224 82. Barrier BF, Bates GW, Leland MM, Leach DA, Robinson RD and Propst AM. Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons. Fertil Steril. 2004;81 Suppl 1:775-9.15019808 83. Koninckx PR, Craessaerts M, Timmerman D, Cornillie F and Kennedy S. Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod. 2008;23:2017-23.18556683 PMC2517154 84. Sikora J, Mielczarek-Palacz A and Kondera-Anasz Z. Association of the Precursor of Interleukin-1beta and Peritoneal Inflammation-Role in Pathogenesis of Endometriosis. J Clin Lab Anal. 2016;30:831-837.27018977 PMC6807114
Claims
1. 1. A method for non-invasively diagnosing endometriosis in a subject, comprising: passing a sample of menstrual discharge (ME) through (i) a 70 μm pore filter or (ii) a filter that allows passage of ME single cells but not ME debris so as to separate ME debris from ME single cells; collecting the ME tissue slice; treating the ME tissue fragments to disaggregate the tissue fragments into cells; subjecting the cells to (i) qPCR and / or digital droplet PCR gene expression analysis, (ii) single-cell RNA sequencing (scRNA-seq) analysis, (iii) flow cytometry, or (iv) protein expression analysis; (1) determining the presence or absence of stromal or epithelial cells that exhibit a phenotype or gene expression pattern associated with endometriosis based on the results of the qPCR or digital droplet PCR gene expression, scRNA-seq analysis, flow cytometry, or protein expression analysis; and / or (2) determining the levels of (a) uterine NK cells, (b) B cells, and / or (c) T cells based on the results of the qPCR gene expression or scRNA-seq analysis, flow cytometry, or protein expression analysis, and determining whether the levels of the uterine NK cells, B cells, and / or T cells are above, below, or within a predetermined control range for the levels of uterine NK cells, B cells, and / or T cells, respectively; Equipped with the presence of stromal cells exhibiting a phenotype, gene expression pattern or protein expression pattern associated with endometriosis indicates that the sample is from a subject with endometriosis; and / or A level of B cells and / or T cells above said predetermined control range and a level of uterine NK cells below said predetermined control range indicates that the sample is from a subject with endometriosis.
2. 1. A method of treating a subject for dysmenorrhea due to endometriosis, comprising: (A) obtaining an identification of the subject's dysmenorrhea as (a) indicative of endometriosis or (b) not indicative of endometriosis, the identification being determined by a method comprising: passing a sample of menstrual discharge (ME) from said subject through a 70 μm pore filter or a filter that allows passage of ME single cells but not ME debris so as to separate ME debris from ME single cells; collecting the ME tissue slice; treating the ME tissue fragments to disaggregate the tissue fragments into cells; subjecting the cells to (i) qPCR gene expression analysis, (ii) scRNA-seq analysis, (iii) flow cytometry, or (iv) mass spectrometry or other protein analysis; and then (1) determining the presence or absence of stromal cells that exhibit a phenotype or gene expression pattern associated with endometriosis based on the results of the qPCR gene expression or scRNA-seq analysis or flow cytometry; and / or (2) determining the levels of (a) uterine NK cells, (b) B cells, and / or (c) T cells based on the results of the qPCR gene expression or scRNA-seq analysis, and determining whether the levels of uterine NK cells, B cells, and / or T cells are above, below, or within a predetermined control range for the levels of uterine NK cells, B cells, and / or T cells, respectively; Equipped with the presence of stromal cells exhibiting a phenotype or gene expression pattern associated with endometriosis indicates that the sample is from a subject with dysmenorrhea indicative of endometriosis; and / or a level of B cells and / or T cells at or above the predetermined control range and a level of uterine NK cells below the predetermined control range indicates that the sample is from a subject with dysmenorrhea indicative of endometriosis; The method of treating a subject with dysmenorrhea for endometriosis may further comprise: (B) treating said subject identified as having dysmenorrhea indicative of endometriosis with a progestin, a progestin and an estrogen, danazol, a gonadotropin releasing hormone agonist, an aromatase inhibitor, or a birth control pill to said subject in an amount effective to treat endometriosis. A method for providing the above.
3. 3. The method of claim 2, wherein a subject identified as having dysmenorrhea not indicative of endometriosis is treated for said dysmenorrhea with a predetermined amount of a nonsteroidal anti-inflammatory drug or other anti-inflammatory drug.
4. 4. The method of claim 1, 2 or 3, further comprising enriching the sample for stromal cells by removing CD45+ cells from the sample prior to performing (i) qPCR gene expression analysis, (ii) scRNA-seq analysis, (iii) flow cytometry, or (iv) mass spectrometry or other protein analysis.
5. 5. The method of any one of claims 1 to 4, further comprising the step of depleting epithelial cells from the sample prior to performing (i) qPCR gene expression analysis, (ii) scRNA-seq analysis, (iii) flow cytometry, or (iv) mass spectrometry or other protein analysis.
6. 6. The method of claim 1, wherein the step of treating the ME tissue fragment to disaggregate the tissue fragment into cells comprises contacting the ME tissue fragment with collagenase, DNase and / or liberase.
7. 7. The method of any one of claims 1 to 6, further comprising freezing and / or storing the cells in a preservative or RNA stabilizing solution before or after disaggregating the tissue pieces.
8. (i) qPCR gene expression analysis, (ii) scRNA-seq analysis, (iii) flow cytometry, or (iv) mass spectrometry or other protein expression analysis; lysing red blood cells in the sample; depleting neutrophils from the sample; and removing dead cells from the sample. The method of claim 1 , further comprising one or more of the following:
9. 9. The method of claim 1, further comprising passing the ME tissue fragments separated from the ME single cells through a second filter having a pore size of 40 μm, and the step of collecting the ME tissue fragments is performed on the ME tissue fragments that do not pass through the second filter.
10. 10. The method of claim 1, wherein the sample is collected in a menstrual cup or a menstrual sponge.
11. 11. The method of any one of claims 1 to 10, further comprising separating the stromal cells, uterine NK cells, B cells and / or T cells from each other using surface markers prior to subjecting the cells to (i) qPCR gene expression analysis, (ii) scRNA-seq analysis, (iii) flow cytometry, or (iv) mass spectrometry or other protein analysis.
12. 12. The method of claim 11, wherein the separation and / or isolation is carried out using fluorescence activated cell sorting or magnetic activated cell sorting.
13. 13. The method of any one of claims 1 to 12, comprising determining the level of stromal cells based on the results of the qPCR gene expression or scRNA-seq analysis.
14. 14. The method of any one of claims 1 to 13, comprising determining the presence or absence of stromal cells that exhibit an endometriosis associated phenotype or gene expression pattern based on the results of the qPCR gene expression or scRNA-seq analysis, but not determining the levels of (a) uterine NK cells, (b) B cells and / or (c) T cells.
15. 14. The method of any one of claims 1 to 13, comprising determining levels of (a) uterine NK cells, (b) B cells and / or (c) T cells based on results of the qPCR gene expression or scRNA-seq analysis, and determining whether the levels of uterine NK cells, B cells and / or T cells are above, below or within a predetermined control range for the levels of uterine NK cells, B cells and / or T cells, respectively.
16. The method of any one of claims 1 to 15, wherein the subject is a human.
17. The method of claim 16 , wherein the subject is an adolescent.
18. 18. The method of any one of claims 1 to 13 or 15 to 17, wherein the predetermined control ranges for B cells, T cells and / or uterine NK cells are determined from one or more ME tissue slices from one or more control subjects not having endometriosis.
19. 1. A method for determining the efficacy of a treatment for endometriosis, comprising: assessing the baseline level in menstrual discharge of stromal cells exhibiting an endometriosis-associated phenotype or gene expression pattern in a subject with endometriosis and / or the levels of (a) uterine NK cells, (b) B cells and / or (c) T cells based on the results of said qPCR gene expression or scRNA-seq analysis or flow cytometry or protein expression analysis by the method of any one of claims 1 or 4 to 18; treating the subject by performing a laparoscopic or hysterectomy on the subject, or administering to the subject an amount of a progestin, a progestin and an estrogen, danazol, a gonadotropin releasing hormone agonist, an aromatase inhibitor, or a birth control pill effective to treat endometriosis; assessing in the subject's menstrual discharge post-treatment levels of stromal cells exhibiting an endometriosis-associated phenotype or gene expression pattern and / or levels of (a) uterine NK cells, (b) B cells, and / or (c) T cells based on the results of said qPCR gene expression or scRNA-seq analysis, or flow cytometry or protein expression analysis; comparing said post-treatment levels to said baseline levels in said subject, wherein an improvement in the level of stromal cells exhibiting a phenotype or gene expression pattern associated with endometriosis and / or an improvement in the levels of (a) uterine NK cells, (b) B cells and / or (c) T cells indicates that the treatment is effective; A method for providing the above.
20. 20. The method of claim 19, further comprising one or more additional iterations of the method to determine when treatment can be stopped, where treatment is stopped if no further improvement in post-treatment levels is observed.
21. 1. A method for preparing a menstrual flow (ME) sample for analysis to enrich the interstitial cell content in said sample from 3% or less to 10% or more, comprising: passing said sample of menstrual discharge (ME) through (i) a 70 μm pore filter or (ii) a filter that allows passage of ME single cells but not ME debris so as to separate ME debris from ME single cells; collecting ME tissue particles that do not pass through the filter; enzymatically treating the ME tissue fragments to disaggregate the tissue fragments into cells; Fixing, permeabilizing and / or freezing the cells in methanol and / or other preservative or RNA stabilizing solutions before or after disaggregating the tissue pieces; Equipped with A method wherein said preparation results in a stromal cell content in said sample of greater than 10%.
22. 22. The method of claim 21, comprising preparing the ME sample for analysis to enrich the stromal cell content in the sample to 20% or more.
23. 23. The method of any one of claims 1 to 22, further comprising the step of obtaining the ME sample from the subject.
24. 24. The method of any one of claims 1 to 23, wherein the stromal cells are stromal fibroblasts (SFCs).
25. 24. The method of any one of claims 1 to 23, wherein the stromal cells are human CD45- / CD326- / CD31- / CD90+ / CD105+ / CD73+.
26. The method of claim 25, wherein the stromal cells are CD140b+.
27. 27. The method of any one of claims 1 to 26, wherein the level of uterine NK cells is determined, and the uterine NK cells are proliferative uterine NK cells.
28. The method of claim 27, wherein said proliferative uterine NK cells are positive for the human marker of proliferation Ki-67 protein (encoded by MKI67).
29. 29. The method of any one of claims 1 to 28, wherein the level of proliferative uterine NK cells in an endometriotic subject sample is at least 4-fold lower than in a control sample from a non-endometriotic subject.
30. 30. The method of any one of claims 1 to 29, wherein the level of proliferative uterine NK cells in an endometriotic subject sample is at least 10-fold lower than in a control sample from a non-endometriotic subject.
31. 31. The method of any one of claims 27 to 30, further comprising the step of selecting proliferative uterine NK cells based on expression of a cell proliferation associated marker.
32. The method of claim 31, wherein the cell proliferation associated marker is a human marker of proliferation Ki-67, CENPF, UBE2C, ASPM, TOP2A, CKS1B, PCLAF or NUSAP1.
33. 33. The method of claim 31 or 32, wherein the cells other than proliferative uterine NK cells are depleted from the sample by a method comprising negative antibody selection.
34. determining the level of uterine NK cells based on the results of the qPCR gene expression or scRNA-seq analysis; 34. A method according to any one of claims 1 to 33, comprising a step of determining whether the expression level of proliferative uterine NK cell human MKI67 or other cell proliferation associated marker is above, below or within a predetermined control range of proliferative uterine NK cell human MKI67 or other cell proliferation associated marker, respectively.
35. 27. A method according to any one of claims 1 to 26, wherein the presence or absence of stromal cells exhibiting a phenotype or gene expression pattern associated with endometriosis is determined.
36. The method of claim 35, wherein the presence of stromal cells in the sample exhibiting higher levels of human matrix Gla protein (MGP), interleukin 11 (IL11) or insulin-like growth factor binding protein 1 (IGFBP1) than a control is indicative of a phenotype or gene expression pattern associated with endometriosis.
37. 37. The method of any one of claims 1 to 36, wherein the stromal cells exhibit a phenotype or gene expression pattern associated with endometriosis, the phenotype or gene expression pattern being a pro-inflammatory or senescent phenotype or gene expression pattern.
38. A kit for non-invasively diagnosing endometriosis in a subject, comprising a sample of menstrual discharge (ME), (i) a 70 μm pore filter or (ii) a filter that allows the passage of ME single cells but not ME tissue fragments, and an amount of collagenase, DNase and / or liberase effective to disaggregate a predetermined amount of ME tissue fragments before or after fixation.
39. 40. The kit of claim 38, further comprising a predetermined amount of a preservative and / or an RNA stabilizing solution.
40. 16. A method of treating endometriosis in a subject, the method comprising the steps of obtaining an identification of the subject as needing treatment for endometriosis, the subject being identified as having endometriosis by the method of any one of claims 1, 4-18 or 23-37; and treating the subject by performing laparoscopic surgery or hysterectomy on the subject or administering to the subject an amount of a progestin, a progestin and an estrogen, danazol, a gonadotropin releasing hormone agonist, an aromatase inhibitor or a birth control pill effective to treat endometriosis.
41. 41. The method of claim 2 or 40, wherein treatment results in relief of one or more of the following symptoms in the subject: chronic pelvic pain, dysmenorrhea, dyspareunia, difficulty in urinating, difficulty in passing bowels, abdominal bloating.
Citation Information
Patent Citations
Methods and compositions for detecting and treating endometriosis
JP2020532305A
Compositions and methods for the treatment of endometriosis
JP2021521803A
Methods for detecting and treating endometriosis
US20210096137A1
Methods for detecting and treating progesterone-resistant infertility
US20230295729A1
